These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 3489128)

  • 1. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New model of a synthetic adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine- induced arthritis: clinical and histologic studies in athymic nude and euthymic rats.
    Kohashi O; Aihara K; Ozawa A; Kotani S; Azuma I
    Lab Invest; 1982 Jul; 47(1):27-36. PubMed ID: 7087395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.
    Chang YH; Pearson CM; Chedid L
    J Exp Med; 1981 Apr; 153(4):1021-6. PubMed ID: 6972989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local tolerance of muroctasin injection in rabbits.
    Nakashima K; Jindo T; Nomura M
    Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
    Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
    J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity of muroctasin in mice, rats and dogs.
    Ono Y; Iwasaki T; Furuhama K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disposition of 14C-muroctasin in laboratory animals.
    Ono K; Masayasu H; Hashimoto F; Yamada M; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1009-14. PubMed ID: 3190792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition.
    Kohashi O; Tanaka A; Kotani S; Shiba T; Kusumoto S; Yokogawa K; Kawata S; Ozawa A
    Infect Immun; 1980 Jul; 29(1):70-5. PubMed ID: 7399708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of muroctasin in mice.
    Matsubayashi K; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic toxicity of muroctasin in mice.
    Ono Y; Sekiguchi M; Aihara K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of muroctasin on the activities of drug metabolizing enzymes in liver microsomes of rats.
    Kamataki T; Komori M; Iwasaki M; Ohi H; Kitada M; Miura T; Ono K
    Arzneimittelforschung; 1988 Jul; 38(7A):1019-22. PubMed ID: 3263867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the stability of muroctasin and degradation products built under extreme conditions.
    Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
    Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.